In 2017, Neelakantan and colleagues first systematically characterized 5amino1mq during screening for selective NNMT inhibitors, with findings published in Biochemical Pharmacology - marking the official discovery and public reporting of the compound.Through structural modification of quinolinebased precursors, the team identified 5amino1mq as a small, membranepermeable molecule with the chemical formula CHN.With an extremely low IC value, it became one of the most promising selective NNMT inhibitors available at the time, with high specificity and no significant inhibition of other metabolically relevant enzymes
Inadequate B12 levels can result in anemia, leading to fatigue and weakness
Deficiency can cause numbness, tingling, and cognitive fog
A licensed healthcare practitioner who is capable of determining the correct dosage and ensuring safe administration should administer these injections
Primary Handling Editor: Sonia Muliyil, in collaboration with the Nature Medicine team